Alembic Pharma News and Updates

Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 3
Author: Deven Choksey

Keep track of all breaking news on Alembic Pharma from all sources in a single place.

Alembic Pharmaceuticals Ltd.

11 Sep 2026

797.85

1.12%

Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with nil observations

Business Line

The company stated that the USFDA conducted an onsite bioequivalence inspection from August 31 to September 10, 2026

Alembic Pharmaceutic.. has an average target of 913.50 from 4 brokers.

Alembic Pharmaceuticals Ltd.

05 Aug 2026

797.85

1.12%

Outlook

Hold: Alembic Pharmaceuticals Ltd.

Target

Deven Choksey

Alembic Pharmaceuticals is well positioned to sustain its growth momentum over the coming quarters, supported by strong traction in the U.S. generics business, a healthy pipeline of limited-competition launches, and the full-quarter contribution from bosutinib following its 180- day exclusivity.

Number of FII/FPI investors decreased from 188 to 179 in Jun 2026 qtr

Alembic Pharmaceuticals Ltd.

04 Aug 2026

797.85

1.12%

Alembic Pharma Q1 net profit up 12.1% at 173.07 cr

Business Line

The company had posted a consolidated net profit of 154.38 crore in the corresponding period of the last fiscal

Alembic Pharmaceutic.. has an average target of 913.50 from 4 brokers.

Alembic Pharma Q1FY27 results: Net profit rises 12% to 173 crore

Business Standard | 04 Aug 2026

Alembic Pharmaceuticals Ltd.

04 Aug 2026

797.85

1.12%

to see Rapid results content

Alembic Pharmaceuticals Ltd.

04 Aug 2026

797.85

1.12%

Outperformance in the US drives an earnings beat in 1Q

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a better-than-expected financial performance with a 12%/19%/13% beat on revenue/EBITDA/PAT for 1QFY27. Strong growth in export formulations and the API segment resulted in a positive earnings surprise for the quarter.

Alembic Pharmaceutic.. has an average target of 913.50 from 4 brokers.

Alembic Pharmaceuticals Ltd.

19 Jul 2026

797.85

1.12%

Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at $1.4 bn

Business Line

Alembic Pharmaceuticals' cumulative tally of USFDA ANDA approvals has risen to 244, comprising 224 final approvals and 20 tentative approvals

Number of FII/FPI investors decreased from 188 to 179 in Jun 2026 qtr

Alembic Pharmaceuticals Ltd.

29 Jun 2026

797.85

1.12%

Alembic Pharmaceuticals gets USFDA nod for generic acne treatment gel

Business Line

The approval by the USFDA is for the abbreviated new drug application (ANDA) of Dapsone gel, 5 per cent

Alembic Pharmaceutic.. has an average target of 913.50 from 4 brokers.

Alembic Pharmaceuticals gets USFDA nod for generic acne treatment gel

Business Standard | 29 Jun 2026

Alembic Pharmaceuticals Ltd.

26 Jun 2026

797.85

1.12%

Alembic Pharma gets USFDA final approval for Oseltamivir oral suspension

Business Line

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Tamiflu Oral Suspension, 6 mg/mL, of Hoffmann-La Roche Inc

Alembic Pharmaceuticals Ltd. is trading below its 30 day SMA of 826.1

Alembic Pharma gets USFDA nod for drug to treat influenza A and B in babies

Business Standard | 26 Jun 2026

Alembic Pharmaceuticals Ltd.

19 Jun 2026

797.85

1.12%

Alembic Pharma gets tentative nod from USFDA for generic cancer drug

Business Line

USFDA's tentative approval is for the ANDA of Binimetinib tablets of strength 45 mg

Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 781.2

Alembic Pharma gets tentative approval from USFDA for generic cancer drug

Business Standard | 19 Jun 2026

Alembic Pharmaceuticals Ltd.

22 May 2026

797.85

1.12%

Alembic Pharma gets USFDA nod for generic levothyroxine sodium tablets

Business Standard

Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic version of levothyroxine sodium tablet indicated as a replacement therapy for hypothyroidism. The approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of levothyroxine sodium tablets of strengths 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, Alembic said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product, Synthroid tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, of AbbVie, Inc, it added. Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism, the company said. Levothyroxine sodium tablets are indicated as .